ClinicalTrials.gg
CompletedNCT00533897Updated Apr 23, 2015Results posted

Phase IIIB Subcutaneous Missed Dose Study

A Phase 3 interventional study of Abatacept and Placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
20th of 63
270 · median 119
Started
2007
with 5 others
Phase 3
26 of 63
2 open now
Registered
17th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 17th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Rheumatoid Arthritis
  • Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1
  • On background methotrexate at least 3 months (≥10mg weekly)
  • Must be able to self injection or allow a care giver to do it for them
  • Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate

Exclusion criteria

Exclusion Criteria:

  • Participants who had prior exposure to abatacept or Ig
  • Received treatment with rituximab.
  • Participants who have received treatment with leflunomide within 1 year of screening
  • Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    Abatacept

    Drug: Abatacept

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)

    Also known as: Orencia, BMS-188667

  • DrugPlacebo

    Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)

06

What researchers measure

Primary outcomes

  1. Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169

    Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: Day 169

  2. Re-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: Day 253 (short term)

Secondary outcomes

  1. RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: Day 253 (short term)

  2. Lead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug

  3. LI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time

    ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

    Time frame: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug

  4. DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. Samples were obtained during treatment (TRT) visits.

    Time frame: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period

  5. DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Post Visits

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: Day 22 after last dose of drug to Day 85 after last dose of drug

  6. DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time

    ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

    Time frame: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period

  7. DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL At Post Visits

    ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

    Time frame: Day 22 after last dose of drug to Day 85 after last dose of drug

  8. RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

    Time frame: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug

  9. RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group

    ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

    Time frame: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug

  10. Short Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups

    Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).

    Time frame: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug

  11. Short Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups

    ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

    Time frame: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug

  12. Short Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups

    The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)

  13. Short Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups

    DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 85, 169, and 253 (short term)

  14. Short Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups

    The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.

    Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)

  15. Short Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups

    The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.

    Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)

  16. LI; Mean Change in DAS 28 (CRP) From Baseline Over Time

    DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 1 (Baseline), 15, 29, 57, 78, 85

  17. LI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time

    DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 15, 29, 57, 78, 85

  18. DBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time

    DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 85 (Period 2 Baseline), 113, 141, and 169

  19. DBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time

    A participant had an RA flare if at least 2 of the following criteria were met: * Doubling of tender and swollen joint count from Day 78 * Increase in DAS28-CRP score ≥ 1.2 from Day 78 * Prematurely discontinued from Double-blind Withdrawal Period (Period 2) and continued to Re-introduction Period (Period 3)

    Time frame: Days 85, 113, 141, and 169

  20. RI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time

    DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

    Time frame: Days 169 (Period III Baseline), 197, 225, and 253

  21. LI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  22. LI Period; Number of Participants With AEs of Special Interest

    AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  23. LI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria

    Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/ microliter (uL); eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  24. LI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  25. LI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  26. LI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

    MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*upper limits of normal (ULN),or if BL\< lower limits of normal (LLN) then use 0.8\*BL or \> upper limits of normal (ULN),or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>ULN,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

    Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier

  27. LI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg). Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 1, 15, 29, 57, 78, and 85

  28. LI Period; Mean Heart Rate (HR)

    Heart rate was taken in participants while seated and measured in beats per minute (bpm). Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 1, 15, 29, 57, 78, and 85

  29. LI Period; Mean Temperature (T)

    Temperature was taken in participants while seated and measured in degrees celsius. Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 1, 15, 29, 57, 78, and 85

  30. DBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  31. DBW; Number of Participants With AEs of Special Interest

    AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  32. DBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  33. DBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  34. DBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  35. DBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

    MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

    Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier

  36. DBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period

    Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).

    Time frame: Days 113, 141, and 169

  37. DBW Period; Mean Heart Rate (HR) During Period 2

    Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)

    Time frame: Days 113, 141, and 169

  38. DBW Period; Mean Temperature (T) During Period II

    Participants were seated and temperature taken just prior to study drug injection.

    Time frame: Days 113, 141, and 169

  39. RI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  40. RI; Number of Participants With AEs of Special Interest

    AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  41. RI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  42. RI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  43. RI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  44. RI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

    MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

    Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.

  45. RI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III

    Time frame: Days 169, 197, 225, and 253

  46. RI Period; Mean Heart Rate (HR) During Period III

    Time frame: Days 169, 197, 225, and 253

  47. RI Period; Mean Temperature (T) During Period III

    Time frame: Days 169, 197, 225, and 253

  48. Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups

    Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.

    Time frame: Day 197 through Day 253

  49. Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups

    Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.

    Time frame: Day 197 through Day 253

  50. ST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups

    Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor. ANA were detected by means of immunofluorescent antibodies. An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation). RF was measured by an immunoturbidimetric assay (Roche Tina-Quant). Determinations of antibody or RF status were made at baseline and Day 253.

    Time frame: Baseline, Day 253

  51. LTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE

    DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. DAS28-CRP has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

    Time frame: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.

  52. LTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE

    DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. Clinical remission=DAS28-CRP score\<2.6. Percent=Number of participants meeting remission divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

    Time frame: For Period I non-responders: as of Study Day 85 and up to Study Day 1821. For ST completers: as of Study Day 253 and up to Study Day 1821

  53. LTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE

    DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. Low disease activity score: ≤ 3.2. Percent=Number of participants with Low Disease Activity divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

    Time frame: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.

  54. LTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE

    The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI. Percent=number of participants with HAQ response divided by number of participants in the analysis. Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.

    Time frame: Study Days 1 (Baseline),15, 29, 57, 78, 85, 253, 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541,1625,1709,1821,1905,1989, 2073

  55. LTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE

    Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL). The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated. Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.

    Time frame: Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, 1989 and 28, 56, 85, 168 days post last dose in LTE

  56. LTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred \> 56 days after the last dose. Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication. All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014), up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.

  57. LTE: Number of Participants With AEs of Special Interest During LTE

    AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014) up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.

  58. LTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE

    Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.

  59. LTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE

    Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.

  60. LTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE

    Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.

  61. LTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE

    MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

    Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.

  62. LTE: Mean Seated Systolic Blood Pressure (SBP) During LTE

    During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261,1345, 1457,1541,1625,1709,1821,1905,1989,2073

  63. LTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE

    During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073

  64. LTE: Mean Heart Rate (HR) During LTE

    During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073

  65. LTE: Mean Temperature (T) During LTE

    During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

    Time frame: Days 337, 365, 449,533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073

07

Results

Posted Jun 3, 2011

Participant flow

Participants with Rheumatoid Arthritis (American College of Rheumatology Class I, II or III) were enrolled. Study initiated November 2007. Short Term (ST) results and some long term extension (LTE) results up to a database lock in 2010 were released earlier. Study concluded February 2014. Final LTE results are now included.

Lead-in (LI) Period 1
Participant flow — Lead-in (LI) Period 1
MilestoneAbatacept (ABA) [Lead-In (LI)]Abatacept (ABA) Double-blind Withdrawal (DBW)Placebo (PLA) Double Blind Withdrawal (DBW)ABA With IV PLA Loading Dose in Re-introduction (RI) PeriodPLA Switched to ABA With ABA IV Loading Dose in RI PeriodPLA Switched to ABA With PLA IV Loading Dose in RI PeriodLong Term Extension Abatacept for LI Period Non-respondersLong Term Extension (LTE) Abatacept for Short Term Completers
Started1670000000
Completed1570000000
Not completed100000000
Withdrew: Adverse event10000000
Withdrew: Participant withdrew consent20000000
Withdrew: Lost to follow-up10000000
Withdrew: Administrative reason by sponsor20000000
Withdrew: Lack of efficacy30000000
Withdrew: Missed 2 consecutive doses of study drug10000000
Double-blind Withdrawal (DBW) Period 2
Participant flow — Double-blind Withdrawal (DBW) Period 2
MilestoneAbatacept (ABA) [Lead-In (LI)]Abatacept (ABA) Double-blind Withdrawal (DBW)Placebo (PLA) Double Blind Withdrawal (DBW)ABA With IV PLA Loading Dose in Re-introduction (RI) PeriodPLA Switched to ABA With ABA IV Loading Dose in RI PeriodPLA Switched to ABA With PLA IV Loading Dose in RI PeriodLong Term Extension Abatacept for LI Period Non-respondersLong Term Extension (LTE) Abatacept for Short Term Completers
Started0408000000
Completed0397700000
Not completed01300000
Withdrew: Lack of efficacy01200000
Withdrew: Poor/non-compliance00100000
Re-introduction (RI) Period 3
Participant flow — Re-introduction (RI) Period 3
MilestoneAbatacept (ABA) [Lead-In (LI)]Abatacept (ABA) Double-blind Withdrawal (DBW)Placebo (PLA) Double Blind Withdrawal (DBW)ABA With IV PLA Loading Dose in Re-introduction (RI) PeriodPLA Switched to ABA With ABA IV Loading Dose in RI PeriodPLA Switched to ABA With PLA IV Loading Dose in RI PeriodLong Term Extension Abatacept for LI Period Non-respondersLong Term Extension (LTE) Abatacept for Short Term Completers
Started00040354400
Completed00040354200
Not completed00000200
Withdrew: Participant withdrew consent00000100
Withdrew: No longer meets study criteria00000100
Long Term Extension (LTE)
Participant flow — Long Term Extension (LTE)
MilestoneAbatacept (ABA) [Lead-In (LI)]Abatacept (ABA) Double-blind Withdrawal (DBW)Placebo (PLA) Double Blind Withdrawal (DBW)ABA With IV PLA Loading Dose in Re-introduction (RI) PeriodPLA Switched to ABA With ABA IV Loading Dose in RI PeriodPLA Switched to ABA With PLA IV Loading Dose in RI PeriodLong Term Extension Abatacept for LI Period Non-respondersLong Term Extension (LTE) Abatacept for Short Term Completers
Started00000037113
Completed0000002488
Not completed0000001325
Withdrew: Participant withdrew consent00000025
Withdrew: Death00000013
Withdrew: Lack of efficacy00000053
Withdrew: Poor/non-compliance00000010
Withdrew: Adverse event00000025
Withdrew: Pregnancy00000002
Withdrew: Lost to follow-up00000011
Withdrew: Other00000016

Outcome measures

PrimaryDouble-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169

Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
Day 169
Reported as:
Number · percentage of participants
Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169
percentage of participantsAbatacept in DBW PeriodPlacebo in DBW Period
Anti-abatacept (n=37, n=71)01.4
Anti-CTLA4-T (n=38, n=73)08.2
Total (n=38, n=73)09.6
Statistical analysis
  • Abatacept in DBW Period vs Placebo in DBW Period · Chi-squared, Corrected · p = 0.119 (There was no adjustment made for multiple comparisons.) · Estimate of difference: 9.59 · 95% CI 0.83 to 18.34
SecondaryRI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
Day 253 (short term)
Reported as:
Number · percentage of participants
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group
percentage of participantsPLA Switched to ABA With ABA IV Loading Dose in RI PeriodPLA Switched to ABA With PLA IV Loading Dose in RI Period
Anti-abatacept (n=32, n=41)00
Anti-CTLA4-T (n=32, n=41)04.9
Total (n=32, n=41)04.9
Statistical analysis
  • PLA Switched to ABA With ABA IV Loading Dose in RI Period vs PLA Switched to ABA With PLA IV Loading Dose in RI Period · Estimate of difference: 4.88 · 95% CI -4.50 to 14.25
SecondaryLead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
Reported as:
Number · percentage of participants
Lead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
percentage of participantsAbatacept in Lead-In Period
Overall on TRT visits: anti-ABA (n=162)1.2
Overall on TRT visits: anti-CTLA4 (n=165)0
Overall on TRT visits: Total (n=165)1.2
Overall post visits: anti-ABA (n=3)0
Overall post visits: anti-CTLA4 (n=3)0
Overall post visits: Total (n=3)0
Overall anti-ABA (n=162)1.2
Overall anti-CTLA4 (n=165)0
Overall Total (n=165)1.2
SecondaryLI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time

ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

Time frame:
For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
Reported as:
Number · percentage of participants
LI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time
percentage of participantsAbatacept in Lead-In Period
Overall onTRT visits CTLA4 and Possibly Ig, n=1651.2
Overall onTRT visits Ig and/or JNC region, n=1650
Overall onTRT visits Total, n=1651.2
Overall post visits CTLA4 and possibly Ig, n=30
Overall post visits Ig and/or JNC region, n=30
Overall post visits: Total, n=30
Overall CTLA4 and possibly Ig, n=1651.2
Overall Ig and/or JNC region, n=1650
Overall Total (n=165)1.2
SecondaryDBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. Samples were obtained during treatment (TRT) visits.

Time frame:
Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
Reported as:
Number · percentage of participants
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
percentage of participantsAbatacept in DBW PeriodPlacebo in DBW Period
Overall on TRT visits: anti-ABA, n=39,7801.3
Overall on TRT visits anti-CTLA4, n=40,8007.5
Overall on TRT visits: Total, n=40,8008.8
PrimaryRe-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
Day 253 (short term)
Reported as:
Number · percentage of participants
Re-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups
percentage of participantsABA in DBW PeriodPlacebo in DBW Period
Anti-abatacept (n=38, n=73)00
Anti-CTLA4-T (n=38, n=73)2.62.7
Total (n=38, n=73)2.62.7
Statistical analysis
  • ABA in DBW Period vs Placebo in DBW Period · Estimate of difference: 0.11 · 95% CI -8.21 to 8.43
SecondaryDBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Post Visits

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
Day 22 after last dose of drug to Day 85 after last dose of drug

No measurements were reported for this outcome.

SecondaryDBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time

ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

Time frame:
Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
Reported as:
Number · percentage of participants
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time
percentage of participantsABA in DBW PeriodPLA in DBW Period
Overall onTRT visits CTLA4 and Possibly Ig,n=40,8006.3
Overall onTRT visits Ig and/or JNC region, n=40,8003.8
Overall on TRT visits: Total Abs, n=40,80010.0
SecondaryDBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL At Post Visits

ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

Time frame:
Day 22 after last dose of drug to Day 85 after last dose of drug

No measurements were reported for this outcome.

SecondaryRI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Time frame:
For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
Reported as:
Number · percentage of participants
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group
percentage of participantsABA [DBW]PLA [DBW]
Overall onTRT visits: anti-ABA, n=39,772.61.3
Overall onTRT visits anti-CTLA4, n=40,785.03.8
Overall onTRT visits: Total, n=40,787.55.1
Overall post visits: anti-ABA, n=1,400
Overall post visits: anti-CTLA4, n=1,4025.0
Overall post visits: Total, n=1,4025.0
SecondaryRI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group

ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

Time frame:
For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
Reported as:
Number · percentage of participants
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group
percentage of participantsABA [DBW]PLA [DBW]
Overall onTRT visits CTLA4 and Possibly Ig,n=40,7800
Overall onTRT visits Ig and/or JNC region, n=40,7800
Overall onTRT visits: Total, n=40,7800
Overall post visits: CTLA4 and possibly Ig, n=1,4100.025.0
Overall post visits: Ig and/or JNC region, n=1,400
Overall post visits: Total, n=1,4100.025.0
SecondaryShort Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups

Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).

Time frame:
For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
Reported as:
Number · percentage of participants
Short Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups
percentage of participantsABA [DBW]PLA [DBW]
Overall study onTRT visits: anti-ABA, n=39,787.71.3
Overall study onTRT visits anti-CTLA4, n=40,805.08.8
Overall study onTRT visits: Total, n=40,8012.510.0
Overall study post visits: anti-ABA, n=1, 400
Overall study post visits: anti-CTLA4, n=1, 4025.0
Overall study post visits: Total, n=1, 4025.0
Overall study anti-ABA, n=39, 787.71.3
Overall study anti-CTLA4, n=40, 805.08.8
Overall study Total, n=40,8012.510.0
SecondaryShort Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups

ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.

Time frame:
For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
Reported as:
Number · percentage of Participants
Short Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups
percentage of ParticipantsABA [DBW]PLA [DBW]
Overall onTRT visits CTLA and possibly Ig,n=40,8007.5
Overall onTRT visits Ig and/or JNC region,n=40,8003.8
Overall study onTRT visits: Total, n=40,80010.0
Overall post visits CTLA4 and possibly Ig,n=1,4100.025.0
Overall post visits: Ig and/or JNC region, n=1,400
Overall study post visits: Total, n=1, 4100.025.0
Overall study CTLA4 and possibly Ig,n=40,802.58.8
Overall study Ig and/or JNC region, n=40, 8003.8
Overall study Total, n=40,802.511.3
SecondaryShort Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups

The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
Reported as:
Mean · units on a scale
Short Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups
units on a scaleABA [DBW]PLA [DBW]
Day 15, n=38, n=75-0.64 ± 0.10-0.87 ± 0.08
Day 29, n=40, n=80-1.07 ± 0.14-1.10 ± 0.09
Day 57, n=40. n=79-1.39 ± 0.14-1.62 ± 0.11
Day 78, n=33, n=76-1.76 ± 0.12-1.89 ± 0.10
Day 85, n=40, n=78-1.97 ± 0.11-1.88 ± 0.11
Day 113, n=39, n=80-1.78 ± 0.18-1.69 ± 0.12
Day 141, n=38, n=76-1.81 ± 0.17-1.54 ± 0.14
Day 169, n=38, n=75-2.03 ± 0.18-1.49 ± 0.14
Day 197, n=40, n=79-2.14 ± 0.16-1.92 ± 0.13
Day 225, n=39, n=77-2.20 ± 0.17-2.04 ± 0.13
Day 253, n=39, n=74-2.22 ± 0.14-2.32 ± 0.12
SecondaryShort Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups

DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 85, 169, and 253 (short term)
Reported as:
Number · percentage of participants
Short Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups
percentage of participantsABA [DBW]PLA [DBW]
Day 85 CMI , n=40, n=788076.9
Day 85 LDAS, n=40, n=7867.562.8
Day 85 Clinical Remission, n=40, n=7835.037.2
Day 169 CMI , n=38, n=7578.957.3
Day 169 LDAS, n=38, n=7568.454.7
Day 169 Clinical Remission, n=38, n=7547.428.0
Day 253 CMI , n=39, n=7487.289.2
Day 253 LDAS, n=39, n=7469.279.7
Day 253 Clinical Remission, n=39, n=7451.363.5
SecondaryShort Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups

The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.

Time frame:
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
Reported as:
Mean · units on a scale
Short Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups
units on a scaleABA [DBW]Placebo (PLA) [DBW]
Day 15, n=40, n=77-0.31 ± 0.06-0.30 ± 0.04
Day 29, n=40, n=80-0.46 ± 0.05-0.35 ± 0.04
Day 57, n=40, n=79-0.58 ± 0.09-0.51 ± 0.06
Day 78, n=33, n=77-0.68 ± 0.10-0.59 ± 0.07
Day 85, n=40, n=79-0.74 ± 0.09-0.63 ± 0.07
Day 113, n=40, n=80-0.69 ± 0.08-0.61 ± 0.06
Day 141, n=39, n=78-0.68 ± 0.10-0.52 ± 0.07
Day 169, n=38, n=76-0.72 ± 0.11-0.50 ± 0.07
Day 197, n=40, n=79-0.76 ± 0.09-0.66 ± 0.06
Day 225, n=40, n=77-0.82 ± 0.10-0.70 ± 0.06
Day 253, n=39, n=74-0.86 ± 0.09-0.72 ± 0.06
SecondaryShort Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups

The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.

Time frame:
Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
Reported as:
Number · percentage of Participants
Short Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups
percentage of ParticipantsABA [DB]PLA [DB]
Day 15, n=40, n=7747.542.9
Day 29, n=40, n=8062.552.5
Day 57, n=40, n=7967.562.0
Day 78, n=33, n=7766.767.5
Day 85, n=40, n=7980.069.6
Day 113, n=40, n=8075.067.5
Day 141, n=39, n=7869.262.8
Day 169, n=38, n=7671.156.6
Day 197, n=40, n=7975.074.7
Day 225, n=40, n=7780.076.6
Day 253, n=39, n=7484.674.3
SecondaryLI; Mean Change in DAS 28 (CRP) From Baseline Over Time

DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 1 (Baseline), 15, 29, 57, 78, 85
Reported as:
Mean · units on a scale
LI; Mean Change in DAS 28 (CRP) From Baseline Over Time
units on a scaleABA [LI]
Day 15, n=150-0.72 ± 0.06
Day 29, n=165-1.00 ± 0.07
Day 57, n=164-1.35 ± 0.08
Day 78, n=143-1.39 ± 0.10
Day 85, n=161-1.53 ± 0.10
SecondaryLI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time

DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 15, 29, 57, 78, 85
Reported as:
Number · percentage of participants
LI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time
percentage of participantsABA [LI]
Day 15, n=15026.0
Day 29, n=16540.6
Day 57, n=16456.1
Day 78, n=14359.4
Day 85, n=16164.6
SecondaryDBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time

DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 85 (Period 2 Baseline), 113, 141, and 169
Reported as:
Mean · units on a scale
DBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time
units on a scaleABA [DBW]PLA [DBW]
Day 113, n=39, n=760.19 ± 0.180.16 ± 0.11
Day 141 , n=38, n=730.14 ± 0.170.35 ± 0.15
Day 169, n=38, n=72-0.06 ± 0.190.40 ± 0.14
SecondaryDBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time

A participant had an RA flare if at least 2 of the following criteria were met: * Doubling of tender and swollen joint count from Day 78 * Increase in DAS28-CRP score ≥ 1.2 from Day 78 * Prematurely discontinued from Double-blind Withdrawal Period (Period 2) and continued to Re-introduction Period (Period 3)

Time frame:
Days 85, 113, 141, and 169
Reported as:
Number · percentage of participants
DBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time
percentage of participantsABA [DB]PLA [DB]
Day 85, n=31, n=6601.5
Day 113, n=33, n=779.12.6
Day 141, n=32, n=736.36.8
Day 169, n=33, n=746.19.5
SecondaryRI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time

DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.

Time frame:
Days 169 (Period III Baseline), 197, 225, and 253
Reported as:
Mean · units on a scale
RI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time
units on a scaleABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 197, n=39, n=33, n=44-0.26 ± 0.17-0.56 ± 0.17-0.50 ± 0.16
Day 225, n=38, n=33, n=42-0.31 ± 0.20-0.59 ± 0.18-0.66 ± 0.17
Day 253, n=38, n=30, n=42-0.23 ± 0.16-0.93 ± 0.20-0.89 ± 0.17
SecondaryLI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation
participantsABA [LI]
Deaths1
SAEs3
Related SAEs0
SAEs Leading to Discontinuation1
AEs82
Related AEs29
AEs Leading to Discontinuation1
SecondaryLI Period; Number of Participants With AEs of Special Interest

AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI Period; Number of Participants With AEs of Special Interest
participantsABA [LI]
Infections and infestations42
Malignancies0
Autoimmune events (prespecified)0
Acute infusional events (prespecified)1
Peri-infusional events (prespecified)2
Local injection site reactions (prespecified)2
Systemic injection reactions (prespecified)9
SecondaryLI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria

Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/ microliter (uL); eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria
participantsABA [LI]
Low HGB0
Low hematocrit0
Low erythrocytes1
Low PLT1
High PLT0
Low leukocytes3
High leukocytes4
Low neutrophils+bands0
High eosinophils1
High basophils0
High monocytes0
Low lymphocytes7
High lymphocytes0
SecondaryLI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
participantsABA [LI]
High ALP0
High AST1
High ALT2
High GGT0
High bilirubin0
High BUN1
High creatinine3
SecondaryLI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria
participantsABA [LI]
Low Na0
High Na0
Low K0
High K0
Low Cl0
High Cl0
Low Ca0
High Ca0
Low P1
High P1
SecondaryLI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*upper limits of normal (ULN),or if BL\< lower limits of normal (LLN) then use 0.8\*BL or \> upper limits of normal (ULN),or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>ULN,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

Time frame:
From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
Reported as:
Number · participants
LI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
participantsABA [LI]
Low Glu (n=167)9
High Glu (n=167)4
Low fasting Glu (n=92)3
High fasting glucose (n=92)0
Low protein (n=167)1
High protein (n=167)1
Low Albumin (n=167)0
High uric acid (n=167)0
High urine protein (n=167)3
High urine Glu (n=167)3
High urine blood (n=167)17
High leukocyte esterase (n=46)9
High urine RBC (n=44)7
High urine WBC (n=63)26
SecondaryLI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg). Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 1, 15, 29, 57, 78, and 85
Reported as:
Mean · mmHg
LI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
mmHgABA [LI]
Day 1 SBP before infusion (n=160)125.0 ± 18.42
Day 15 SBP before injection (n=156)122.3 ± 14.55
Day 29 SBP before injection (n=161)122.0 ± 14.02
Day 57 SBP before injection (n=157)121.4 ± 14.87
Day 78 SBP before injection (n=157)120.3 ± 14.38
Day 85 SBP before injection (n=159)122.0 ± 15.19
Day 1 DBP before infusion (n=160)76.0 ± 10.88
Day 15 DBP before injection (n=156)75.8 ± 9.63
Day 29 DBP before injection (n=161)76.1 ± 9.43
Day 57 DBP before injection (n=157)75.7 ± 9.82
Day 78 DBP before injection (n=157)75.4 ± 10.29
Day 85 DBP before injection (n=159)75.2 ± 9.45
SecondaryLI Period; Mean Heart Rate (HR)

Heart rate was taken in participants while seated and measured in beats per minute (bpm). Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 1, 15, 29, 57, 78, and 85
Reported as:
Mean · bpm
LI Period; Mean Heart Rate (HR)
bpmABA [LI]
Day 1 HR before infusion (n=167)73.9 ± 9.78
Day 15 HR before injection (n=160)76.0 ± 7.91
Day 29 HR before injection (n=166)75.5 ± 9.03
Day 57 HR before injection (n=164)75.5 ± 8.95
Day 78 HR before injection (n=158)75.1 ± 7.78
Day 85 HR before injection (n=160)74.7 ± 8.64
SecondaryLI Period; Mean Temperature (T)

Temperature was taken in participants while seated and measured in degrees celsius. Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 1, 15, 29, 57, 78, and 85
Reported as:
Mean · degrees Celsius
LI Period; Mean Temperature (T)
degrees CelsiusABA [LI]
Day 1 T before infusion (n=167)36.39 ± 0.387
Day 15 T before injection (n=160)36.34 ± 0.351
Day 29 T before injection (n=166)36.39 ± 0.371
Day 57 T before injection (n=164)36.38 ± 0.329
Day 78 T before injection (n=158)36.33 ± 0.333
Day 85 T before injection (n=160)36.35 ± 0.368
SecondaryDBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
participantsABA [DBW]Placebo (PLA) [DBW]
Deaths02
SAEs02
Related SAEs00
AEs Leading to Discontinuation00
AEs1329
Related AEs29
AEs Leading to Discontinuation00
SecondaryDBW; Number of Participants With AEs of Special Interest

AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With AEs of Special Interest
participantsABA [DBW]Placebo (PLA) [DBW]
Infections and infestations57
Malignancies00
Autoimmune disorders (prespecified)00
Acute infusional events (prespecified)00
Peri-infusional events (prespecified)00
Local injection site reactions (prespecified)00
Systemic injection reactions (prespecified)11
SecondaryDBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
participantsABA [DBW]PLA [DBW]
Low HGB (n=40, n=80)00
Low hematocrit (n=39, n=79)00
Low erythrocytes (n=40, n=80)00
Low PLT (n=40, n=80)00
High PLT (n=40, n=80)00
Low leukocytes (n=40, n=80)01
High leukocytes (n=40, n=80)00
Low neutrophils+bands (n=40, n=80)00
High eosinophils (n=40, n=80)02
High basophils (n=40, n=80)00
High monocytes (n=40, n=80)00
Low lymphocytes (n=40, n=80)24
High lymphocytes (n=40, n=80)00
SecondaryDBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
participantsABA [DBW]PLA [DBW]
High ALP00
High AST00
High ALT10
High GGT20
High bilirubin00
High BUN00
High creatinine01
SecondaryDBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
participantsABA [DBW]PLA [DBW]
Low Na00
High Na00
Low K00
High K00
Low Cl00
High Cl00
Low Ca00
High Ca00
Low P00
High P00
SecondaryDBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

Time frame:
From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
Reported as:
Number · participants
DBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
participantsABA [DBW]PLA [DBW]
Low Glu (n=40, n=80)25
High Glu (n=40, n=80)13
Low fasting Glu (n=27, n=51)01
High fasting Glu (n=27, n=51)01
Low total protein (n=40, n=80)00
High total protein (n=40, n=80)00
Low albumin (n=40, n=80)00
High uric acid (n=40, n=80)00
High urine protein (n=40, n=80)10
High urine Glu (n=40, n=80)01
High urine blood (n=40, n=80)310
High leukocyte esterase (n=10, n=21)14
High urine RBC (n=13, n=23)15
High urine WBC (n=15, n=28)612
SecondaryDBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period

Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).

Time frame:
Days 113, 141, and 169
Reported as:
Mean · mm mercury (Hg)
DBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period
mm mercury (Hg)ABA [DBW]PLA [DBW]
Day 113 SBP before injection (n=39, n=78)119.4 ± 13.29120.4 ± 15.60
Day 141 SBP before injection (n=39, n=76)120.3 ± 12.73121.2 ± 14.98
Day 169 SBP before injection (n=40, n=80)119.6 ± 13.87119.4 ± 14.11
Day 113 DBP before injection (n=39, 78)74.2 ± 10.4474.4 ± 9.34
Day 141 DBP before injection (n=39, n=76)76.3 ± 10.4676.0 ± 10.60
Day 169 DBP before injection (n=40, n=80)74.0 ± 9.5174.7 ± 8.94
SecondaryDBW Period; Mean Heart Rate (HR) During Period 2

Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)

Time frame:
Days 113, 141, and 169
Reported as:
Mean · beats per minute (bpm)
DBW Period; Mean Heart Rate (HR) During Period 2
beats per minute (bpm)ABA [DBW]PLA [DBW]
Day 113 HR before injection (n=40, n=78)75.8 ± 8.0773.9 ± 8.39
Day 141 HR before injection (n=39, n=76)75.9 ± 9.3574.5 ± 8.45
Day 169 HR before injection (n=40, n=80)73.8 ± 8.1974.2 ± 8.50
SecondaryDBW Period; Mean Temperature (T) During Period II

Participants were seated and temperature taken just prior to study drug injection.

Time frame:
Days 113, 141, and 169
Reported as:
Mean · degrees Celsius
DBW Period; Mean Temperature (T) During Period II
degrees CelsiusABA [DBW]PLA [DBW]
Day 113 T before infusion (n=40, n=78)36.34 ± 0.48836.44 ± 0.370
Day 141 T before injection (n=39, n=76)36.31 ± 0.35536.36 ± 0.347
Day 169 T before injection (n=40, n=80)36.38 ± 0.36436.32 ± 0.373
SecondaryRI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Deaths000
SAEs001
Related SAEs000
SAEs Leading to Discontinuation000
AEs151716
Related AEs144
AEs Leading to Discontinuation000
SecondaryRI; Number of Participants With AEs of Special Interest

AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With AEs of Special Interest
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Infections and infestations787
Malignancies000
Autoimmune disorders (prespecified)000
Acute infusional events (prespecified)000
Peri-infusional events (prespecified)001
Local injection site reactions (prespecified)000
Systemic injection reactions (prespecified)001
SecondaryRI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Low HGB000
Low hematocrit000
Low erythrocytes000
Low PLT000
High PLT000
Low leukocytes000
High leukocytes010
Low neutrophils+bands000
High eosinophils000
High basophils000
High monocytes000
Low lymphocytes200
High lymphocytes000
SecondaryRI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
High ALP000
High AST000
High ALT200
High GGT100
High bilirubin000
High BUN000
High creatinine000
SecondaryRI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Low Na000
High Na000
Low K001
High K000
Low Cl000
High Cl000
Low Ca000
High Ca000
Low P010
High P000
SecondaryRI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria

MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

Time frame:
From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
Reported as:
Number · participants
RI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
participantsABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Low Glu (n=40, n=35, n=44)111
High Glu (n=40, n=35, n=44)010
Low fasting Glu (n=27, n=20, n=28)100
High fasting glucose (n=27, n=20, n=28)000
Low total protein (n=40, n=35, n=44)000
High total protein (n=40, n=35, n=44)000
Low albumin (n=40, n=35, n=44)000
High uric acid (n=40, n=35, n=44)000
High urine protein (n=40, n=35, n=44)001
High urine glucose (n=40, n=34, n=44)000
High urine blood (n=40, n=35, n=44)647
High leukocyte esterase (n=14, n=8, n=7)421
High urine RBC (n=17, n=14, n=15)636
High urine WBC (n=19, n=15, n=15)654
SecondaryRI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III
Time frame:
Days 169, 197, 225, and 253
Reported as:
Mean · mm mercury (Hg)
RI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III
mm mercury (Hg)ABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 169 SBP before infusion (n=39, n=35, n=44)121.3 ± 15.81116.6 ± 14.78118.9 ± 13.32
Day 197 SBP before injection (n=40, n=35, n=43)119.1 ± 14.07118.4 ± 15.62121.0 ± 14.45
Day 225 SBP before injection (n=40, n=35, n=42)117.8 ± 14.19118.8 ± 16.55121.0 ± 16.88
Day 253 SBP before injection (n=40, 35, n=43)118.3 ± 15.00116.1 ± 14.86120.3 ± 16.01
Day 169 DBP before infusion (n=39, n=35, n=44)74.7 ± 10.4673.5 ± 9.6174.9 ± 9.15
Day 197 DBP before injection (n=40, n=35, n=43)72.9 ± 9.2471.6 ± 7.6674.9 ± 9.51
Day 225 DBP before injection (n=40, n=35, n=42)73.6 ± 10.5673.7 ± 7.8475.5 ± 10.65
Day 253 DBP before injection (n=40, n=35, n=44)74.7 ± 11.2471.5 ± 9.9276.3 ± 11.02
SecondaryRI Period; Mean Heart Rate (HR) During Period III
Time frame:
Days 169, 197, 225, and 253
Reported as:
Mean · beats per minute (bpm)
RI Period; Mean Heart Rate (HR) During Period III
beats per minute (bpm)ABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 169 HR before infusion (n=40, n=35, n=44)73.4 ± 8.5473.8 ± 10.1374.1 ± 9.35
Day 197 HR before injection (n=40, n=35, n=43)73.1 ± 7.5275.1 ± 7.2570.9 ± 8.87
Day 225 HR before injection (n=40, n=35, n=42)73.2 ± 7.073.9 ± 7.4373.2 ± 7.60
Day 253 HR before injection (n=40, n=35, n=43)73.6 ± 8.5374.4 ± 7.8774.3 ± 9.36
SecondaryRI Period; Mean Temperature (T) During Period III
Time frame:
Days 169, 197, 225, and 253
Reported as:
Mean · degrees Celsius
RI Period; Mean Temperature (T) During Period III
degrees CelsiusABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 169 T before infusion (n=40, n=35, n=44)36.32 ± 0.42336.29 ± 0.47336.26 ± 0.396
Day 197 T before injection (n=40, n=35, n=43)36.39 ± 0.40536.37 ± 0.42436.35 ± 0.354
Day 225 T before injection (n=40, n=35, n=42)36.27 ± 0.37536.38 ± 0.44436.36 ± 0.320
Day 253 T before injection (n=40, n=34, n=42)36.28 ± 0.47336.32 ± 0.58736.33 ± 0.383
SecondaryShort Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.

Time frame:
Day 197 through Day 253
Reported as:
Mean · ug/mL
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups
ug/mLABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 197 seropositive (n=2, n=1, n=1)39.17 ± 10.51033.73 ± NA18.05 ± NA
Day 197 seronegative (n=33, n=32, n=40)34.45 ± 10.57835.67 ± 10.36522.76 ± 8.740
Day 225 seropositive (n=0, n=1, n=1)NA ± NA34.18 ± NA21.69 ± NA
Day 225 seronegative (n=36, n=29, n=41)27.86 ± 9.51431.70 ± 10.63529.24 ± 13.897
Day 253 seropositive (n=1, n=0, n=2)29.49 ± NANA ± NA26.23 ± 0.776
Day 253 seronegative (n=34, n=30, n=39)30.17 ± 9.85628.26 ± 10.21126.80 ± 10.547
SecondaryShort Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.

Time frame:
Day 197 through Day 253
Reported as:
Mean · ug/mL
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups
ug/mLABA With IV PLA Loading Dose [RI]PLA Switched to ABA With ABA IV Loading Dose [RI]PLA Switched to ABA With PLA IV Loading Dose [RI]
Day 197 seropositive (n=0, n=0, n=0)NA ± NANA ± NANA ± NA
Day 197 seronegative (n=35, n=33, n=41)34.72 ± 10.47935.61 ± 10.20722.65 ± 8.662
Day 225 seropositive (n=0, n=0, n=0)NA ± NANA ± NANA ± NA
Day 225 seronegative (n=36, n=30, n=42)27.86 ± 9.51431.79 ± 10.46029.06 ± 13.776
Day 253 seropositive (n=0, n=0, n=0)NA ± NANA ± NANA ± NA
Day 253 seronegative (n=36, n=30, n=42\)29.75 ± 9.87228.26 ± 10.21126.28 ± 10.645
SecondaryST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups

Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor. ANA were detected by means of immunofluorescent antibodies. An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation). RF was measured by an immunoturbidimetric assay (Roche Tina-Quant). Determinations of antibody or RF status were made at baseline and Day 253.

Time frame:
Baseline, Day 253
Reported as:
Number · participants
ST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups
participantsABA [DBW]Placebo (PLA) [DBW]
BL ANA negative (n=27, n=57)13
BL ANA positive (n=11, 18)510
BL dsDNA negative (n=33, n=63)12
BL dsDNA positive (n=3, n=6)23
BL RF negative (n=6, n=10)00
BL RF positive (n=34, n=64)3463
SecondaryLTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE

DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. DAS28-CRP has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

Time frame:
For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
Reported as:
Mean · units on a scale
LTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE
units on a scaleLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Study Day 15; Treatment Day 15 (n=31, 106)-0.48 ± 0.14-0.79 ± 0.06
Study Day 85; Treatment Day 85 (n=36, 112)-0.35 ± 0.21-1.91 ± 0.09
Study Day 253; Treatment Day 85 (n=0, n=109)NA ± NA-2.29 ± 0.09
Study Day 337; Treatment Day 169 (n=34,n=113)-1.51 ± 0.16-2.34 ± 0.09
Study Day 365; Treatment Day 197 (n=31, n=110)-1.83 ± 0.19-2.23 ± 0.10
Study Day 533; Treatment Day 365 (n=32, n=106)-1.86 ± 0.19-2.28 ± 0.12
Study Day 729; Treatment Day 561 (n=30, n=106-1.81 ± 0.19-2.16 ± 0.12
Study Day 1093; Treatment Day 925 (n=26, n=98)-1.94 ± 0.18-2.12 ± 0.12
Study Day 1261; Treatment Day 1093 (n=25, n=96)-1.70 ± 0.15-2.20 ± 0.13
Study Day 1821; Treatment Day 1653 (n=20, n=67)-1.86 ± 0.20-2.55 ± 0.14
SecondaryLTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE

DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. Clinical remission=DAS28-CRP score\<2.6. Percent=Number of participants meeting remission divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

Time frame:
For Period I non-responders: as of Study Day 85 and up to Study Day 1821. For ST completers: as of Study Day 253 and up to Study Day 1821
Reported as:
Number · percentage of participants
LTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE
percentage of participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Study Day 85 (n=36, n=112)11.136.6
Study Day 253 (n=0, n=109)NA59.6
Study Day 337 (n=34, n=113)50.059.3
Study Day 729 (n=30, n=106)53.354.7
Study Day 1093 (n=26, 90)73.151.0
Study Day 1261 (n=25, n=96)48.059.4
Study Day 1821 (n=20, n=67)60.059.7
SecondaryLTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE

DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. Low disease activity score: ≤ 3.2. Percent=Number of participants with Low Disease Activity divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.

Time frame:
For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
Reported as:
Number · percentage of participants
LTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE
percentage of participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Study Day 85 (n=36, n=112)27.866.1
Study Day 253 (n=0, n=109)NA75.2
Study Day 337 (n=34, n=113)67.676.1
Study Day 729 (n=30, n=106)73.373.6
Study Day 1093 (n=26, n=98)80.867.3
Study Day 1261 (n=25, n=96)68.075.0
Study Day 1821 (n=20, n=67)80.088.1
SecondaryLTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE

The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI. Percent=number of participants with HAQ response divided by number of participants in the analysis. Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.

Time frame:
Study Days 1 (Baseline),15, 29, 57, 78, 85, 253, 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541,1625,1709,1821,1905,1989, 2073
Reported as:
Number · percentage of participants
LTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE
percentage of participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Study Day 15; Treatment Day 15 (n=34, n=110)20.6 (7.0 to 34.2)44.5 (35.3 to 53.8)
Study Day 29; Treatment Day 29 (n=36, n=113)27.8 (13.1 to 42.4)56.6 (47.5 to 65.8)
Study Day 57; Treatment Day 57 (n=36, n=112)44.4 (28.2 to 60.7)64.3 (55.4 to 73.2)
Study Day 78; Treatment Day 78 (n=34, n=103)41.2 (24.6 to 57.7)68.0 (58.9 to 77.0)
Study Day 85; Treatment Day 85 (n=37, n=112)40.5 (24.7 to 56.4)74.1 (66.0 to 82.2)
Study Day 253; Treatment Day 85 (n=0, n=109)NA (NA to NA)78.0 (70.2 to 85.8)
Study Day 337; Treatment Day 169 (n=34, n=113)50.0 (33.2 to 66.8)79.6 (72.2 to 87.1)
Study Day 365; Treatment Day 197 (n=32, n=111)53.1 (35.8 to 70.4)78.4 (70.7 to 86.0)
Study Day 449; Treatment Day 281 (n=32, n=109)56.3 (39.1 to 73.4)73.4 (65.1 to 81.7)
Study Day 533; Treatment Day 365 (n=32, n=108)59.4 (42.4 to 76.4)72.2 (63.8 to 80.7)
Study Day 617; Treatment Day 449 (n=31, n=107)54.8 (37.3 to 72.4)70.1 (61.4 to 78.8)
Study Day 729; Treatment Day 561 (n=30, n=107)60.0 (42.5 to 77.5)70.1 (61.4 to 78.8)
Study Day 813; Treatment Day 645 (n=30, n=106)53.3 (35.5 to 71.2)71.7 (63.1 to 80.3)
Study Day 897; Treatment Day 729 (n=30, n=103)50.0 (32.1 to 67.9)76.7 (68.5 to 84.9)
Study Day 981; Treatment Day 813 (n=29, n=100)44.8 (26.7 to 62.9)73.0 (64.3 to 81.7)
Study Day 1093; Treatment Day 925 (n=28, n=99)50.0 (31.5 to 68.5)73.7 (65.1 to 82.4)
Study Day 1177; Treatment Day 1009 (n=26, n=99)61.5 (42.8 to 80.2)68.7 (59.6 to 77.8)
Study Day 1261; Treatment Day 1093 (n=25, n=97)60.0 (40.8 to 79.2)70.1 (61.0 to 79.2)
Study Day 1345; Treatment Day 1177 (n=25, n=89)64.0 (45.2 to 82.8)70.8 (61.3 to 80.2)
Study Day 1457; Treatment Day 1289 (n=24, n=79)66.7 (47.8 to 85.5)72.2 (62.3 to 82.0)
Study Day 1541; Treatment Day 1373 (n=21, n=75)61.9 (41.1 to 82.7)69.3 (58.9 to 79.8)
Study Day 1625; Treatment Day 1457 (n=21, n=73)52.4 (31.0 to 73.7)74.0 (63.9 to 84.0)
Study Day 1709; Treatment Day 1541 (n=20, n=71)60.0 (38.5 to 81.5)74.6 (64.5 to 84.8)
Study Day 1821; Treatment Day 1653 (n=20, n=68)65.0 (44.1 to 85.9)73.5 (63.0 to 84.0)
Study Day 1905; Treatment Day 1737 (n=19, n=5)63.2 (41.5 to 84.8)80.0 (44.9 to 100.0)
Study Day 1989; Treatment Day 1821 (n=19, n=0)68.4 (47.5 to 89.3)NA (NA to NA)
Study Day 2073; Treatment Day 1905 (n=5, n=0)100.0 (100.0 to 100.0)NA (NA to NA)
SecondaryLTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE

Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL). The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated. Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.

Time frame:
Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, 1989 and 28, 56, 85, 168 days post last dose in LTE
Reported as:
Number · percentage of participants
LTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE
percentage of participantsLTE Abatacept for All Participants
Overall Study (n=149)20.1
Overall on Treatment Visit Days (n=147)15.6
28 Days post last dose (n=110)7.3
56 Days post last dose (n=16)6.3
85 Days post last dose (n=103)7.8
168 Days post last dose (n=21)23.8
Overall Post Visits (n=126)12.7
SecondaryLTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred \> 56 days after the last dose. Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication. All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014), up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Deaths16
Related SAEs03
SAEs Leading to Discontinuation15
Related AEs945
AEs Leading to Discontinuation25
SecondaryLTE: Number of Participants With AEs of Special Interest During LTE

AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014) up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With AEs of Special Interest During LTE
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Infections and infestations2378
Malignancies13
Autoimmune disorders (prespecified)38
Local injection site reactions (prespecified)03
Systemic injection reactions (prespecified)311
SecondaryLTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE

Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Low HGB14
Low hematocrit02
Low erythrocytes01
Low PLT01
Low leukocytes15
High leukocytes06
Low neutrophils+bands02
High eosinophils314
Low lymphocytes59
SecondaryLTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
High AST03
High ALT22
High GGT18
High bilirubin01
High BUN07
High creatinine411
SecondaryLTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE

Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
High Na10
Low K03
High Cl10
Low P05
High P10
SecondaryLTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE

MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3

Time frame:
For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
Reported as:
Number · participants
LTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE
participantsLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Low Glu (n=35, n=113)616
High Glu (n=35, n=113)16
Low fasting Glu (n=14, n=75)42
High fasting Glu (n=14, n=75)06
Low total protein (n=35, n=113)10
Low albumin (n=35, n=113)10
High urine protein (n=35, n=113)211
High urine Glu (n=35, n=113)13
High urine blood (n=35, n=113)530
High urine WBC (n=22, n=81)1239
High urine RBC (n=16, n=66)127
High leukocyte esterase (n=19, n=67)618
SecondaryLTE: Mean Seated Systolic Blood Pressure (SBP) During LTE

During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261,1345, 1457,1541,1625,1709,1821,1905,1989,2073
Reported as:
Mean · mm Hg
LTE: Mean Seated Systolic Blood Pressure (SBP) During LTE
mm HgLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Day 337 (n=35, n=110)125.7 ± 13.76120.8 ± 15.92
Day 365 (n=32, n=108)122.7 ± 14.26120.4 ± 15.11
Day 449 (n=32, n=108)122.9 ± 15.08119.5 ± 14.88
Day 533 (n=32, n=108)123.0 ± 14.48120.7 ± 15.75
Day 617 (n= 30, n=107)121.7 ± 13.26118.7 ± 15.30
Day 729 (n=30, n=106)122.2 ± 11.77121.5 ± 17.41
Day 813 (n=30, n=101)126.6 ± 12.66120.6 ± 15.65
Day 897 (n=30, n=102)123.9 ± 11.92122.5 ± 14.92
Day 981 (n=28, n=100)123.3 ± 12.23122.9 ± 15.03
Day 1093 (n=26, n=99)127.2 ± 18.41123.7 ± 15.11
Day 1177 (n=25, n=96)125.8 ± 11.17123.0 ± 15.96
Day 1261 (n=25, n=92)124.9 ± 11.04119.7 ± 13.64
Day 1345 (n=24, n=82)124.5 ± 13.11121.9 ± 14.49
Day 1457 (n=21, n=79)124.1 ± 14.75125.5 ± 18.41
Day 1541 (n=21, n=79)126.1 ± 15.06122.3 ± 14.53
Day 1625 (n=21, n=77)122.4 ± 9.09120.3 ± 13.76
Day 1709 (n=21, n=74)123.0 ± 13.08121.9 ± 14.90
Day 1821 (n=20, n=33)125.4 ± 13.22124.3 ± 10.95
Day 1905 (n=18, n=0)121.8 ± 13.14NA ± NA
Day 1989 (n=13, n=0)124.6 ± 9.56NA ± NA
Day 2073 (n=1, n=0)113.0 ± 0NA ± NA
SecondaryLTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE

During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
Reported as:
Mean · mmHg
LTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE
mmHgLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Day 337 (n=35, 110)76.3 ± 6.6975.4 ± 11.18
Day 365 (n=32, 108)75.1 ± 10.4275.1 ± 8.94
Day 449 (n=32, n=108)77.3 ± 9.4873.8 ± 9.12
Day 533 (n=32, n=108)75.5 ± 8.4375.4 ± 9.14
Day 617 (n=30, n=107)74.2 ± 8.8174.8 ± 9.45
Day 729 (n=30, n=106)73.2 ± 8.4276.1 ± 9.86
Day 813 (n=30, n=101)75.7 ± 9.3976.4 ± 9.30
Day 897 (n=30, n=102)76.8 ± 8.4175.5 ± 9.09
Day 981 (n=28, n=100)77.4 ± 6.5576.1 ± 9.67
Day 1093 (n=26, n=99)76.7 ± 7.1175.9 ± 9.88
Day 1177 (n=25, n=96)76.3 ± 6.3275.9 ± 8.58
Day 1261 (n=25, n=92)75.4 ± 8.1875.6 ± 8.59
Day 1345 (n=24, n=82)75.3 ± 6.0875.6 ± 9.03
Day 1457 (n=21, n=79)75.6 ± 9.1877.1 ± 10.04
Day 1541 (n=21, n=79)76.9 ± 8.1476.0 ± 9.15
Day 1625 (n=21, n=77)77.2 ± 5.8974.9 ± 9.01
Day 1709 (n=21, n=74)75.0 ± 9.4775.4 ± 9.09
Day1821 (n=20, n=33)76.0 ± 7.9978.3 ± 7.57
Day 1905 (n=18, n=0)73.2 ± 7.96NA ± NA
Day 1989 (n=13, n=0)77.0 ± 5.31NA ± NA
Day 2073 (n=1, n=0)69.0 ± 0NA ± NA
SecondaryLTE: Mean Heart Rate (HR) During LTE

During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
Reported as:
Mean · bpm
LTE: Mean Heart Rate (HR) During LTE
bpmLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Day 337 (n=35, n=110)74.3 ± 7.0774.9 ± 8.76
Day 365 (n=32, n=109)74.2 ± 7.7675.7 ± 8.45
Day 449 (n=32, n=108)74.4 ± 6.6275.7 ± 7.76
Day 533 (n=32, n=108)75.8 ± 6.6274.7 ± 8.32
Day 617 (n=30, n=107)75.7 ± 6.9676.0 ± 8.35
Day 729 (n=30, n=106)74.2 ± 8.6075.1 ± 8.70
Day 813 (n=30, n=103)72.4 ± 7.5776.2 ± 9.23
Day 897 (n=30, n=102)76.1 ± 7.7176.3 ± 8.15
Day 981 (n=28, n=100)74.4 ± 8.0076.5 ± 10.75
Day 1093 (n=26, n=99)76.3 ± 8.3575.0 ± 9.20
Day 1177 (n=25, n=97)77.6 ± 6.8975.3 ± 9.00
Day 1261 (n=25, n=92)75.7 ± 7.9774.4 ± 8.91
Day 1345 (n=24, n=82)73.5 ± 8.5473.6 ± 8.62
Day 1457 (n=21, n=79)75.0 ± 7.6776.8 ± 7.96
Day 1541 (n=21, n=79)77.3 ± 7.3475.1 ± 8.51
Day 1625 (n=21, n=77)76.9 ± 7.7775.2 ± 8.12
Day 1709 (n=21, n=74)78.7 ± 6.8674.7 ± 8.83
Day 1821 (n=20, n=33)79.5 ± 7.8078.2 ± 6.78
Day 1905 (n=18, n=0)77.1 ± 8.97NA ± NA
Day 1989 (n= 13, n=0)77.2 ± 9.53NA ± NA
Day 2073 (n=1, n=0)63.0 ± 0NA ± NA
SecondaryLTE: Mean Temperature (T) During LTE

During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.

Time frame:
Days 337, 365, 449,533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
Reported as:
Mean · degrees Celsius
LTE: Mean Temperature (T) During LTE
degrees CelsiusLTE Abatacept for LI Period 1 Non-respondersLTE Abatacept for Short Term Completers
Day 337 (n=35, n=110)36.29 ± 0.28536.31 ± 0.370
Day 365 (n=32, n=108)36.35 ± 0.37036.30 ± 0.393
Day 449 (n=32, n=108)36.40 ± 0.35436.30 ± 0.294
Day 533 (n=32, n=108)36.42 ± 0.35836.30 ± 0.312
Day 617 (n=30, n=106)36.38 ± 0.24836.37 ± 0.316
Day 729 (n=30, n=106)36.47 ± 0.25236.27 ± 0.332
Day 813 (n=30, n=103)36.49 ± 0.28436.30 ± 0.324
Day 897 (n=30, n=102)36.44 ± 0.25436.26 ± 0.325
Day 981 (n=28, n=100)36.48 ± 0.25936.30 ± 0.295
Day 1093 (n=26, n=99)36.35 ± 0.37036.28 ± 0.278
Day 1177 (n=25, n=97)36.41 ± 0.27736.24 ± 0.327
Day 1261 (n=25, n=92)36.39 ± 0.25636.24 ± 0.276
Day 1345 (n=24,n=82)36.29 ± 0.28536.23 ± 0.232
Day 1457 (n=21, n=79)36.32 ± 0.25336.23 ± 0.242
Day 1541 (n=21, n=79)36.34 ± 0.22336.24 ± 0.198
Day 1625 (n=21, n=77)36.37 ± 0.21536.20 ± 0.214
Day 1709 (n=21, n=74)36.35 ± 0.17836.24 ± 0.249
Day 1821 (n=20, n=33)36.25 ± 0.31536.26 ± 0.228
Day 1905 (n=18, n=0)36.37 ± 0.211NA ± NA
Day 1989 (n=13, n=0)36.35 ± 0.139NA ± NA
Day 2073 (n=1, n=0)36.40 ± 0NA ± NA

Adverse events

Collected over Day 1 up to 56 days post last dose, through LTE (for those participating in LTE); Day 1 up to 56 days post last dose until final day of study for Period 1 non-completers.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1 Non-Completers—2/10 (20%)6/10 (60%)
Period 1 Non-Responders—12/37 (32.4%)29/37 (78.4%)
Abatacept Received in Period 2—11/40 (27.5%)33/40 (82.5%)
Placebo Received in Period 2—27/80 (33.8%)66/80 (82.5%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPeriod 1 Non-CompletersPeriod 1 Non-RespondersAbatacept Received in Period 2Placebo Received in Period 2
CholelithiasisHepatobiliary disorders1/100/371/400/80
CellulitisInfections and infestations1/101/370/400/80
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/100/370/400/80
OsteoarthritisMusculoskeletal and connective tissue disorders0/102/370/403/80
Tendon ruptureInjury, poisoning and procedural complications0/101/370/400/80
Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders0/101/370/400/80
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/101/370/400/80
Upper gastrointestinal haemorrhageGastrointestinal disorders0/101/370/400/80
Renal colicRenal and urinary disorders0/101/370/400/80
Stress urinary incontinenceRenal and urinary disorders0/101/370/400/80
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPeriod 1 Non-CompletersPeriod 1 Non-RespondersAbatacept Received in Period 2Placebo Received in Period 2
Upper respiratory tract infectionInfections and infestations0/1014/3712/4018/80
BronchitisInfections and infestations0/1011/379/4018/80
Urinary tract infectionInfections and infestations0/106/3710/4015/80
InfluenzaInfections and infestations0/109/375/4014/80
SinusitisInfections and infestations1/106/376/4016/80
DiarrhoeaGastrointestinal disorders0/101/376/406/80
NasopharyngitisInfections and infestations1/104/376/408/80
HypertensionVascular disorders0/103/373/4010/80
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/101/375/406/80
Back painMusculoskeletal and connective tissue disorders0/104/373/407/80

Baseline characteristics

All Period 1 Non-responders and Period 2 participants who received at least one dose of abatacept during the study were summarized.

Age, Continuous
Age, Continuous(years)Period 1 Non-RespondersAbatacept Received in Period 2Placebo Received in Period 2Total
Mean53.4 ± 12.748.9 ± 14.249.1 ± 12.849.8 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Period 1 Non-RespondersAbatacept Received in Period 2Placebo Received in Period 2Total
Female303467131
Male761326
08

Study locations

27 sites
  • Wallace Rheumatic Study Center
    Los Angeles, California 90048, United States
  • New England Research Associates, Llc
    Trumbull, Connecticut 06611, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Diagnostic Rheumatology And Research,Pc
    Indianapolis, Indiana 46227, United States
  • Klein And Associates, M.D., Pa
    Cumberland, Maryland 21502, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Center For Assessment And Research Of Erie
    Erie, Pennsylvania 16508, United States
  • Columbia Arthritis Center
    Columbia, South Carolina 29204, United States
  • Mountain State Clinical Research
    Clarksburg, West Virginia 26301, United States
  • Local Institution
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Santa Fe, 3000, Argentina
  • Local Institution
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Mexico City, Distrito Federal 06726, Mexico
  • Local Institution
    Metepec, Estado De Mexico 52140, Mexico
  • Local Institution
    Leon, Guanajuato 37520, Mexico
  • Local Institution
    Merida, Yucatan 97000, Mexico
  • Local Institution
    Bloemfontein, Free State 9317, South Africa
  • Local Institution
    Muckleneuk, Gauteng 0002, South Africa
  • Local Institution
    Pretoria, Gauteng 0084, South Africa
  • Local Institution
    Berea, Kwa Zulu Natal 4001, South Africa
  • Local Institution
    Panorama, Western Cape 7500, South Africa
09

References and documents

Publications

  • Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis. 2012 Jan;71(1):38-44. doi: 10.1136/annrheumdis-2011-200344. Epub 2011 Sep 13. PubMed 21917824 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2008 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2007
First posted
Sep 24, 2007
Start
Nov 2007
Primary completionActual
Dec 2008
CompletionActual
Feb 2014
Results first posted
Jun 3, 2011
Last update
Apr 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00533897
Responsible party
Sponsor
First posted
Sep 24, 2007
Start date
Nov 2007
Primary completion
Dec 2008
Completion
Feb 2014
Results posted
Jun 3, 2011
Last update
Apr 23, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion